Author(s):
Gaurav Nanda, Mohit Mangla, Manish Yadav, Shaveta Ahalwat
Email(s):
mohitpharmacist@gmail.com
DOI:
10.52711/0974-360X.2026.00105 
Address:
Gaurav Nanda1, Mohit Mangla1*, Manish Yadav1, Shaveta Ahalwat2
1Department of Pharmacy, School of Healthcare and Allied Sciences, GD Goenka University, Gurugram, India.
2University Institute of Pharma Sciences, Chandigarh University, Mohali, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 2,
Year - 2026
ABSTRACT:
Atorvastatin is a popular statin medication, classified as a BCS class-II medication, which has poor aqueous solubility and immediate release, and lower bioavailability, altering its medical efficacy with potential side effects. To overcome these challenges, the current study utilized the Quality-based design (QbD) approach to optimize atorvastatin calcium (AVC) nanoparticles via central composite design of Design Expert® software. Independent variables inputs were Eudragit S100 (100-500mg) as pH-sensitive polymer and PVA (1-5ml) as stabilizer, while the analyzed responses were particle size (nm), drug loading (%), and percentage drug release (%). Initially, the pre-formulation studies confirmed the compatibility of AVC with the polymer. ANOVA analysis in response surface graphs depicted a higher F-value and an insignificant lack of fit (p-value) for all dependent variables, confirming the significance of the model. Out of the 13 formulations suggested by the software, the formulation containing 354.28mg of Eudragit S100 and 3.79ml of PVA was selected as the best optimized formulation for nanoparticle development with a 0.726 desirability value. The optimized nanoparticles exhibited 385.6nm particle size, 86.2% entrapment efficiency, and 83.4% drug release. The optimized AVC nanoparticle also revealed a 0.235 poly-dispersibility index (PDI), 42.7mV zeta potential, and sustained release pattern for intestinal targeting. This approach helps in establishing a statistically validated formulation process by overcoming the limitations, which signifies the potential for targeted and controlled drug delivery applications.
Cite this article:
Gaurav Nanda, Mohit Mangla, Manish Yadav, Shaveta Ahalwat. Development and Optimization of Sustained Release Atorvastatin-Loaded Polymeric Nanoparticles using Quality by Design (QbD) Approach. Research Journal of Pharmacy and Technology. 2026;19(2):722-0. doi: 10.52711/0974-360X.2026.00105
Cite(Electronic):
Gaurav Nanda, Mohit Mangla, Manish Yadav, Shaveta Ahalwat. Development and Optimization of Sustained Release Atorvastatin-Loaded Polymeric Nanoparticles using Quality by Design (QbD) Approach. Research Journal of Pharmacy and Technology. 2026;19(2):722-0. doi: 10.52711/0974-360X.2026.00105 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-2-34
REFERENCES:
1. More S, Lokhande S, Raje V. Review on solid lipid nanoparticles for ophthalmic delivery. Research Journal of Pharmaceutical Dosage Forms and Technology. 2019; 11(1): 19-34. https://doi.org/10.5958/0975-4377.2019.00004.1
2. Sahu L, Nagwanshi P, Sahu P, Sahu A, Sahu G, Sharma H. Novel Approaches of Treatment of Cancer: Nanoparticle. Research Journal of Pharmaceutical Dosage Forms and Technology. 2020; 12(2): 115-24. https://doi.org/10.5958/0975-4377.2020.00021.X
3. Tulbah AS. Inhaled atorvastatin nanoparticles for lung cancer. Current Drug Delivery. 2022; 19(10): 1073-82. https://doi.org/10.2174/1567201819666220426091500
4. Shoiab AA, Gardouh A, Alsarhan A, Al-hamad N. The comparison between the effect of atorvastatin and nanoparticle atorvastatin on rat liver. Biomedical and Pharmacology Journal. 2023; 16(1): 237-41. https://doi.org/10.13005/bpj/2605
5. Clementino AR, Marchi C, Pozzoli M, Bernini F, Zimetti F, Sonvico F. Anti-inflammatory properties of statin-loaded biodegradable lecithin/chitosan nanoparticles: a step toward nose-to-brain treatment of neurodegenerative diseases. Frontiers in Pharmacology. 2021; 12: 716380. https://doi.org/10.3389/fphar.2021.716380
6. Arafa MG, Girgis GN, El-Dahan MS. Chitosan-coated PLGA nanoparticles for enhanced ocular anti-inflammatory efficacy of atorvastatin calcium. International Journal of Nanomedicine. 2020; 15: 1335-47. https://doi.org/10.2147/IJN.S237314
7. Lavanya V, Rajeswari P, Vidyavathi M, Sureshkumar RV. Preparation of atorvastatin loaded chitosan nanoparticles: in vitro and in vivo evaluations. International Journal of Nanoscience. 2020; 19(5): 1950036. https://doi.org/10.1142/S0219581X19500364
8. Bhattacharjee S, Dutta G, Guha N, Banerjee D, Roy T, Maiti S. Formulation and evaluation study of Azithromycin tablets by various natural polymers and their comparative preformulation study. Research J. Pharm. and Tech. 2018; 11(3): 1107-1111. https://doi.org/10.5958/0974-360X.2018.00208.1
9. Wei J, Chen S, Fu H, Wang X, Li H, Lin J, Xu F, He C, Liang X, Tang H, Shu G. Measurement and correlation of solubility data for atorvastatin calcium in pure and binary solvent systems from 293.15 K to 328.15 K. Journal of Molecular Liquids. 2021; 324: 115124. https://doi.org/10.1016/j.molliq.2020.115124
10. Kanakagiri D, Omprakash H, Kumar KM, Vishwanadham Y. Formulation and evaluation of pantoprazole delayed release tablets using Eudragit L30D55. Research Journal of Pharmacy and Technology. 2017; 10(2): 421-425. https://doi.org/10.5958/0974-360X.2017.00084.1
11. Prathyusha P, Sundararajan R. UV spectrophotometric method for determination of Bilastine in bulk and pharmaceutical formulation. Research Journal of Pharmacy and Technology. 2020; 13(2): 933-938. https://doi.org/10.5958/0974-360X.2020.00176.6
12. Baghwan RR, Ambekar AW, Tamboli SS. Formulation, development and evaluation of in-situ periodontal gel containing ofloxacin. Research Journal of Pharmacy and Technology. 2021; 14(9): 4609-4. https://doi.org/10.52711/0974-360X.2021.00801
13. Shaji J, Kumbhar M. Linezolid Loaded Biodegradable Polymeric Nanoparticles Formulation and Characterization. Research Journal of Pharmaceutical Dosage Forms and Technology. 2018; 10(4): 272-8. https://doi.org/10.5958/0975-4377.2018.00040.X
14. Ahmed IS, El Hosary R, Hassan MA, Haider M, Abd-Rabo MM. Efficacy and safety profiles of oral atorvastatin-loaded nanoparticles: effect of size modulation on biodistribution. Molecular Pharmaceutics. 2018; 15(1): 247-55. https://doi.org/10.1021/acs.molpharmaceut.7b00856
15. Gambhire VM, Salunkhe SM, Gambhire MS. Atorvastatin-loaded lipid nanoparticles: antitumor activity studies on MCF-7 breast cancer cells. Drug Development and Industrial Pharmacy. 2018; 44(10): 1685-92. https://doi.org/10.1080/03639045.2018.1492605
16. Das V, Bhairav B, Saudagar RB. Quality by Design approaches to Analytical Method Development. Research Journal of Pharmacy and Technology. 2017; 10(9): 3188-3194. https://doi.org/10.5958/0974-360X.2017.00567.4
17. Ahalwat S, Bhatt DC, Rohilla S. Fabrication of lipid combination for bioavailability enhancement of Isoniazid. Research Journal of Pharmacy and Technology. 2022; 15(12): 5589-96. https://doi.org/10.52711/0974-360X.2022.00944
18. Ahalwat S, Bhatt DC. Development of novel lipid matrix for improved sustained release effect of a hydrophilic drug via response surface methodology. Journal of Drug Delivery Science and Technology. 2022; 67: 102993. https://doi.org/10.1016/j.jddst.2021.102993
19. Ozturk AA, Yenilmez E, Yazan Y. Dexketoprofentrometamol-loaded Eudragit® RL 100 nanoparticle formulation, characterization and release kinetics. Acta Pharmaceutica Sciencia, 2019; 57(1): 69-84. https://doi.org/10.23893/1307-2080.APS.05705
20. Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Delivery 2016; 23(2): 395-404. https://doi.org/10.3109/10717544.2014.914986
21. Gite S, Chogale M, Patravale V. Development and validation of a discriminating dissolution method for atorvastatin delayed-release nanoparticles using a flow-through cell: a comparative study using USP apparatus 4 and 1. Dissolution Technologies. 2016; 23(2): 14-20. https://doi.org/10.14227/DT230216P14
22. Veni DK, Gupta NV. Quality by Design approach in the development of Solid Lipid Nanoparticles of Linagliptin. Research Journal of Pharmacy and Technology. 2019; 12(9): 4454-4462. https://doi.org/10.5958/0974-360X.2019.00768.6
23. Ahalwat S, Bhatt DC, Rohilla S. Quality by Design (QbD) based formulation optimization of Isoniazid loaded novel nanostructured lipid carriers for controlled release effect. Journal of Pharmaceutical Innovation. 2023; 18: 1685–1700. https://doi.org/10.1007/s12247-023-09749-y
24. Maharini I, Martien R, Nugroho AK, Adhyatmika S. Validation UV spectrophotometric method to determine entrapment efficiency of ocular polymeric nanoparticle Levofloxacin hemihydrate. Research Journal of Pharmacy and Technology. 2021; 14(10): 5479-82. https://doi.org/10.52711/0974-360X.2021.00956
25. Patel AJ, Singh RP, Patel V, Goswami S. Application of mathematical models in drug release kinetics of Lagerstroemia speciosa extract- phospholipid complex. Research Journal of Pharmacy and Technology. 2022; 15(3): 1257-62. https://doi.org/10.52711/0974-360X.2022.00210
26. Ahalwat S, Bhatt DC, Rohilla S, Jogpal V, Sharma K, Virmani T, Kumar G, Alhalmi A, Alqahtani AS, Noman OM, Almoiliqy M. Mannose-functionalized Isoniazid- loaded nanostructured lipid carriers for pulmonary delivery: In vitro prospects and in vivo therapeutic efficacy assessment. Pharmaceuticals (Basel). 2023; 16(8): 1108. https://doi.org/10.3390/ph16081108. PMID: 37631023
27. Bayer IS. Controlled drug release from nanoengineered polysaccharides. Pharmaceutics. 2023; 15(5): 1364. https://doi.org/10.3390/pharmaceutics15051364
28. Fan Y, Marioli M, Zhang K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. Journal of Pharmaceutical and Biomedical Analysis. 2021; 192: 113642. https://doi.org/10.1016/j.jpba.2020.113642